



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit [go.covermymeds.com/OptumRx](http://go.covermymeds.com/OptumRx) to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

## Humira® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting <b>brand</b>			Directions for Use:		
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>					
Clinical Information (required)					
<b>Select the diagnosis below:</b>					
<input type="checkbox"/> Ankylosing spondylitis (for example; M45.0; M45.9)					
<input type="checkbox"/> Crohn's disease (for example; K50.00; K50.919; K50.019)					
<input type="checkbox"/> Hidradenitis suppurativa (for example; L73.2)					
<input type="checkbox"/> Plaque psoriasis (for example; psoriasis vulgaris; psoriasis; L40.0; L40.8; L40.9)					
<input type="checkbox"/> Polyarticular juvenile idiopathic arthritis (for example; M08.09; M08.40)					
<input type="checkbox"/> Psoriatic arthritis (for example; arthropathic psoriasis; L40.5; L40.59)					
<input type="checkbox"/> Rheumatoid arthritis (for example; M05.79; M06.9)					
<input type="checkbox"/> Ulcerative colitis (for example; ulcerative pancolitis; K51.00; K51.90; K51.919)					
<input type="checkbox"/> Uveitis (for example; Iridocyclitis; H20; H20.9)					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
<b>Clinical Information:</b>					
Select if Humira is prescribed by or in consultation with one of the following specialist(s):					
<input type="checkbox"/> Dermatologist					
<input type="checkbox"/> Gastroenterologist					
<input type="checkbox"/> Ophthalmologist					
<input type="checkbox"/> Rheumatologist					
<b>For ankylosing spondylitis, also answer the following:</b>					
Is the patient's disease active? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Has the patient had a trial and failure, contraindication, or intolerance to TWO non-steroidal anti-inflammatory drugs (NSAIDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>For Crohn's disease, also answer the following:</b>					
Is the patient's disease moderately to severely active? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Select if the patient has had a trial and failure, contraindication, or intolerance to the following conventional therapies:					
<input type="checkbox"/> 6-mercaptopurine					
<input type="checkbox"/> Azathioprine (Imuran)					
<input type="checkbox"/> Corticosteroid (e.g., prednisone, methylprednisolone)					
<input type="checkbox"/> Methotrexate (Rheumatrex, Trexall)					
Has the patient had a trial and failure (i.e., lost response) or intolerance to infliximab? <input type="checkbox"/> Yes <input type="checkbox"/> No					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Humira\_CMS\_2020May-V



**Humira® Prior Authorization Request Form (Page 2 of 2)**  
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

**For hidradenitis suppurativa, also answer the following:**

Is the patient's disease moderate to severe (that is, Hurley Stage II or III)?  Yes  No

**For plaque psoriasis, also answer the following:**

Is the patient's disease chronic and moderate to severe?  Yes  No

**For polyarticular juvenile idiopathic arthritis (JIA), also answer the following:**

Is the patient's disease moderately to severely active?  Yes  No

Has the patient had a trial and failure, contraindication, or intolerance to Arava (leflunomide) OR Rheumatrex/Trexall (methotrexate)?  Yes  No

**For psoriatic arthritis, also answer the following:**

Is the patient's disease active?  Yes  No

**For rheumatoid arthritis (RA), also answer the following:**

Is the patient's disease moderately to severely active?  Yes  No

Has the patient had a trial and failure, contraindication, or intolerance to one disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate (Rheumatrex/Trexall), leflunomide (Arava), sulfasalazine (Azulfidine)]?  Yes  No

**For ulcerative colitis, also answer the following:**

Is the patient's disease moderately to severely active?  Yes  No

Select if the patient has had a trial and failure, contraindication, or intolerance to the following conventional therapies:

- 6-mercaptopurine
- Aminosalicylate [e.g., mesalamine (Asacol, Pentasa, Rowasa), Dipentum (olsalazine), Azulfidine (sulfasalazine)]
- Azathioprine (Imuran)
- Corticosteroid (e.g., prednisone, methylprednisolone)

**For uveitis, also answer the following:**

Is the patient's disease non-infectious?  Yes  No

Select the patient's uveitis classification:

- Intermediate
- Panuveitis
- Posterior

**Reauthorization:**

**If this is a reauthorization request, answer the following:**

Is there documentation the patient has had a positive clinical response to Humira therapy?  Yes  No

**For ulcerative colitis, also answer the following:**

For patients who initiated Humira therapy within the past 12 weeks: Is there documentation the patient has experienced clinical remission or significant clinical benefit by eight weeks (Day 57) of therapy?  Yes  No

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

---

Please note:

This request may be denied unless all required information is received.  
If the patient is not able to meet the above standard prior authorization requirements, please call 1-800-711-4555.  
For urgent or expedited requests please call 1-800-711-4555.  
This form may be used for non-urgent requests and faxed to 1-844-403-1028.